8-K
filed June 2, 2026, 8:04 AM ET
ticker URGN
CIK 0001668243
other material
confidence high
sentiment neutral
materiality 0.65
UroGen settles patent litigation with Teva over Jelmyto; generic entry Sept 15, 2030
UroGen Pharma Ltd.
- Settlement resolves patent litigation regarding Teva's generic version of Jelmyto (mitomycin) for pyelocalyceal solution.
- Teva granted non-exclusive license to sell generic Jelmyto starting September 15, 2030, if FDA approved.
- All ongoing patent litigation between the parties in U.S. District Court for Delaware will be terminated.
- Agreement is subject to review by U.S. Federal Trade Commission and U.S. Department of Justice.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001437749-26-019102
- form_type
- 8-K
- ticker
- URGN
- cik
- 0001668243
- company_name
- UroGen Pharma Ltd.
- filed_at
- 2026-06-02T12:04:53+00:00
- discovered_at
- 2026-06-02T12:10:00.309939+00:00
- generated_at
- 2026-06-02T12:11:27.712432+00:00
- sec_items
- ["8.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001437749-26-019102
- json_url
- https://secwatch.observer/filing/0001437749-26-019102.json
- markdown_url
- https://secwatch.observer/filing/0001437749-26-019102.md
- text_url
- https://secwatch.observer/filing/0001437749-26-019102.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1668243/000143774926019102/0001437749-26-019102-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1668243/000143774926019102/urgn20260601_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
XMTR
Xometry announces public offering of 2.65M shares at $85.00; expected net proceeds $215.2M
Xometry, Inc.
June 2, 2026, 5:26 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
ARVN
Arvinas to out-license ARV-806 after completing Phase 1 dose escalation
ARVINAS, INC.
June 2, 2026, 4:39 PM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
TTI
TETRA announces $100M common stock offering, Arkansas Bromine Project approved with $220M remaining capex
TETRA TECHNOLOGIES INC
June 2, 2026, 4:26 PM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
CEG
Constellation Energy secondary offering of 11M shares with concurrent $558M share repurchase
Constellation Energy Corp
June 2, 2026, 4:15 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
INMB
INmune Bio reports statistically significant white matter MRI biomarker in Phase 2 Alzheimer's trial
Inmune Bio, Inc.
June 2, 2026, 4:00 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
MBOT
Microbot Medical secures first North Carolina customer for LIBERTY robotic system
Microbot Medical Inc.
June 2, 2026, 8:30 AM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
ASST
Strive purchases 2,500 bitcoin at avg $74,092; total holdings rise to 19,000
Strive, Inc.
June 2, 2026, 8:00 AM ET
other_material
Items 8.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
SAIA
Saia reports April/May LTL shipments up 5.6%/3.7%, tonnage up 6.9%/8.4% YoY
SAIA INC
June 2, 2026, 7:45 AM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.